Update on angioedema: Evaluation, diagnosis, and treatment

Allergy and Asthma Proceedings

Volumn 32, Issue 6, 2011, Pages 408-412

  Bernstein, Jonathan A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANDROGEN; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 12; BRADYKININ; CINRYZ; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ACNE; ALOPECIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; C1 INHIBITOR DEFICIENCY; CAPILLARY LEAK SYNDROME; CLINICAL FEATURE; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEFICIENCY; CONFERENCE PAPER; DERMATITIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG HALF LIFE; DYSPHONIA; EOSINOPHILIA; FATIGUE; GENOTYPE; HIRSUTISM; HUMAN; INDUCED HYPOTENSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIBIDO DISORDER; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MISSENSE MUTATION; MOOD CHANGE; MUCKLE WELLS SYNDROME; MUSCLE CRAMP; NAUSEA; NONHUMAN; ONSET AGE; PATHOGENESIS; PRACTICE GUIDELINE; PROTEIN SECRETION; RECURRENT DISEASE; RHEUMATIC DISEASE; SIDE EFFECT; SUBSTITUTION THERAPY; SWELLING; TERATOGENICITY; THROMBOSIS; TUMOR GROWTH; VERTIGO; WEAKNESS; WEIGHT GAIN;

ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PEPTIDYL-DIPEPTIDASE A;

EID: 84455208652     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3469     Document Type: Conference Paper

References (43)

1. Epstein TG, and Bernstein JA. Current and emerging management options for hereditary angioedema in the US. Drugs 68: 2561-2573, 2008.
2. Abraham D, and McGrath KG. Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. Allergy Asthma Proc 24:291-294, 2003. (Pubitemid 37152337)
3. Banerji A, Oren E, et al. Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy/immunology consult service. Allergy Asthma Proc 29:88-92, 2008.
4. Banerji A, Weller PF, and Sheikh J. Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich's Syndrome). Immunol Allergy Clin North Am 26:769-781, 2006. (Pubitemid 44755114)
5. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
6. Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 18:1289-1298, 1988.
7. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: A review of the pathophysiology and risk factors. Clin Exp Allergy 40:50-61, 2009.
8. Jesus AA, Oliveira JB, Hilario MO, et al. Pediatric hereditary autoinflammatory syndromes. J Pediatr (Rio J) 86:353-366, 2010.
9. Kapoor P, Greipp PT, Schaefer EW, et al. Idiopathic systemic capillary leak syndrome (Clarkson's disease): The Mayo clinic experience. Mayo Clin Proc 85:905-912, 2010.
10. Kimura G. Pathogenesis of edema and its classification. Nippon Rinsho 63:11-6, 2005.
11. Ohmoto K, and Yamamoto S. Angioedema after interferon therapy for chronic hepatitis C. Am J Gastroenterol 96:1311-1312, 2001. (Pubitemid 32319194)
12. Huntington JA. Shape-shifting serpins-advantages of a mobile mechanism. Trends Biochem Sci 31:427-435, 2006.
13. Zuraw BL, and Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 105:541-546, 2000. (Pubitemid 30169913)
14. Nzeako UC, Frigas E, and Tremaine WJ. Hereditary angioedema: A broad review for clinicians. Arch Intern Med 161: 2417-2429, 2001. (Pubitemid 33043115)
15. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. J Allergy Clin Immunol 126:918-925, 2010.
16. Davis AE III. The pathogenesis of hereditary angioedema. Transfus Apher Sci 29:195-203, 2003.
17. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109:1057-1063, 2002. (Pubitemid 34408580)
18. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006. (Pubitemid 43255068)
19. Khan DA. Hereditary angioedema: Historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis. Allergy Asthma Proc 32:1-10, 2011.
20. Kemp JG, and Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: A literature review. Allergy Asthma Proc 30:493-499, 2009.
21. Prematta MJ, Kemp JG, Gibbs JG, et al. Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc 30:506-511, 2009.
22. Zuraw BL, and Christiansen SC. Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc 30:487-492, 2009.
23. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 286:808-812, 1972.
24. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 295:1444-1448, 1976. (Pubitemid 8003704)
25. Banerji A, Sloane DE, and Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V: Attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 100(suppl 2):S19-22, 2008.
26. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
27. Zuraw BL. Hereditary angioedema: A current state-of-the-art review, IV: Short- and long-term treatment of hereditary angioedema: Out with the old and in with the new? Ann Allergy Asthma Immunol 100(suppl 2):S13-S18, 2008.
28. Riedl MA. Update on the acute treatment of hereditary angioedema. Allergy Asthma Proc 32:11-16, 2010.
29. Zuraw BL. HAE therapies: Past present and future. Allergy Asthma Clin Immunol 6:23, 2010.
30. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513-522, 2010.
31. Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 30:823-829, 2010.
32. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 6:22, 2010.
33. Bernstein JA, and Qazi M. Ecallantide: Its pharmacology, pharmacokinetics, clinical efficacy, and tolerability. Expert Rev Clin Immunol 6:29-39, 2010.
34. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523-531, 2010.
35. Stolz LE, and Horn PT. Ecallantide: A plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema. Drugs Today (Barc) 46:547-555, 2010.
36. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532-541, 2010.
37. Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 9:310-323, 2008. (Pubitemid 351323385)
38. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31:407-414, 2010.
39. Bernstein JA, Coleman S, and Bonnin AJ. Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema. J Cardiothorac Surg 5:86, 2010.
40. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356:213-217, 2000. (Pubitemid 30446977)
41. Cicardi M, and Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol 6:14, 2010.
42. Byrd JB, Adam A, and Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 26:725-737, 2006. (Pubitemid 44679724)
43. Byrd JB, Shreevatsa A, Putlur P, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 120:403-408, 2007. (Pubitemid 47102380)